Nos publications
Immunothérapies et thérapies ciblées
-
Journal of the American Medical Association
Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial
-
Annals of the Rheumatic Diseases
Development and psychometric validation of a patient-reported outcome measure to assess fears in rheumatoid arthritis and axial spondyloarthritis: the Fear Assessment in Inflammatory Rheumatic diseases (FAIR) questionnaire
-
Journal for Immunotherapy of Cancer
Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival
-
Annals of the Rheumatic Diseases
Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)
-
Annals of the Rheumatic Diseases
Cell-specific epigenome-wide DNA methylation profile in long-term cultured minor salivary gland epithelial cells from patients with Sjögren's syndrome
-
Arthritis & Rheumatology
Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases
-
Kidney International
An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants
-
Journal for Immunotherapy of Cancer
STIM1 at the plasma membrane as a new target in progressive chronic lymphocytic leukemia
-
Chest
Eosinophilic Granulomatosis With Polyangiitis: Clinical Predictors of Long-term Asthma Severity
-
European J Cancer
Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events
-
Nature Reviews Rheumatology
ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients
-
Nature Reviews Rheumatology
Treatment of primary Sjögren syndrome